Key Takeaways
- General Dynamics (GD) has secured a substantial €3.5 billion contract from the German Bundeswehr for 274 next-generation reconnaissance vehicles, part of a larger €7 billion German defense procurement initiative.
- AbbVie's (ABBV) Rinvoq demonstrated superior efficacy over Humira in a head-to-head Phase 3b/4 study for rheumatoid arthritis, with 43.3% of Rinvoq patients achieving low disease activity compared to 22.4% on Humira.
- Canadian business confidence remains weak, primarily due to persistent U.S. tariffs impacting investment and hiring, with 33% of businesses and 64.1% of consumers now expecting a recession.
- AI startup Cohere, backed by Nvidia (NVDA), is enabling a secondary share sale for employees ahead of a potential IPO, following a recent valuation of approximately $7 billion and annualized revenue surging to $150 million.
- Google (GOOGL, GOOG) is launching a "Trusted Tester" program, inviting 15 "Superfans" to confidentially test upcoming Pixel phones and provide feedback, a notable shift in its pre-release strategy.
Defense contractor General Dynamics (GD) has landed a significant €3.5 billion contract with the German Bundeswehr for the development and procurement of 274 reconnaissance vehicles. This agreement is a cornerstone of Germany's broader €7 billion defense initiative to modernize its military fleet, with deliveries of the reconnaissance vehicles expected to commence in 2028. The overall defense package includes an additional €3.4 billion for 150 "Schakal" wheeled armored infantry fighting vehicles from Artec GmbH, with potential options to expand both orders.
In the pharmaceutical sector, AbbVie (ABBV) announced positive topline results from its SELECT-SWITCH Phase 3b/4 head-to-head study, showing its newer arthritis drug Rinvoq (upadacitinib) to be superior to its long-standing bestseller, Humira (adalimumab), in treating moderate to severe rheumatoid arthritis. The study revealed that 43.3% of patients on Rinvoq achieved low disease activity (DAS28-CRP≤3.2) at week 12, significantly outperforming Humira, which saw 22.4% of patients reach the same endpoint. This development is crucial for AbbVie as it seeks to offset declining Humira sales due to biosimilar competition.
The Bank of Canada (BoC) reported that business confidence remains subdued, largely due to the persistent impact of U.S. tariffs on investment and hiring decisions. The central bank's quarterly business outlook survey indicated a marginal improvement in sentiment from early 2025 lows but noted that many firms are delaying new investments and maintaining subdued hiring intentions. Furthermore, the survey highlighted growing recession concerns, with 33% of businesses and 64.1% of consumers now anticipating a recession within the next year, potentially paving the way for a BoC interest rate cut.
In the rapidly evolving artificial intelligence landscape, Nvidia (NVDA)-backed AI startup Cohere is facilitating a secondary share sale, allowing employees to cash out shares ahead of a potential initial public offering (IPO). The company, co-headquartered in Toronto and San Francisco, was recently valued at approximately $7 billion after securing around $1.6 billion in funding, including a $500 million round in August. Cohere's annualized revenue has reportedly surged to $150 million, underscoring strong enterprise demand for its AI solutions.
Google (Alphabet) (GOOGL, GOOG) is embarking on a novel approach to product testing with the launch of its "Trusted Tester" program for upcoming Pixel phones. The program will select just 15 "Superfans" who demonstrate exceptional knowledge and passion for the Pixel brand to receive early access to unreleased devices. Participants will be required to sign strict non-disclosure agreements (NDAs) and use protective cases to disguise the hardware, providing critical feedback directly to Google's development teams.
Finally, Brazil's Finance Minister Fernando Haddad stated that President Lula's administration is on track to achieve the best fiscal result since 2015 by the end of his term. The deficit reduction is attributed to the government's efforts in reducing business subsidies for the first time. While details on specific subsidy cuts were not immediately available, Haddad's comments underscore a commitment to fiscal responsibility.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.